Anti-inflammatory medicines

Inflammation and prostaglandins

Inflammation involves several biological mediators and can accompany very different conditions. NSAIDs act particularly on prostaglandin synthesis by inhibiting enzymes called cyclo-oxygenases. Their profiles are not identical across substances. Analgesic or antipyretic actions may also be described for selected members, but those functions do not make every pain medicine equivalent to an NSAID. Paracetamol, for example, must not be presented as an NSAID simply because it is used for pain. The distinction between a symptom-related role and a pharmacological family gives these terms their precise meaning.

Systemic routes and local preparations

Tablets, capsules and other systemic forms differ from gels and cutaneous preparations. Route is a central pharmaceutical characteristic; it does not establish that a local form has no systemic effects or is interchangeable with an oral preparation. Formulations and indications remain medicine-specific. Topical products in the musculoskeletal field can also contain different compositions, which need to be described completely rather than reduced to one familiar substance or a sensation produced on the skin. Similar destinations do not turn them into one uniform anti-inflammatory preparation.

Families and comparison limits

Non-steroidal distinguishes NSAIDs from corticosteroids, whose mechanisms and use frameworks differ. Gel concentration, content per tablet and unit count are not a universal potency scale. Modified-release or gastro-resistant formulations add particular pharmaceutical properties without establishing a general promise of protection or tolerability. Information on risks, interactions and settings of use remains specific to the medicines. This precision explains the family without equating anti-inflammatory action, analgesia and disease-modifying treatment for a joint disorder, which describe related but different functions within musculoskeletal care.

Frequently asked questions